PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34491490-1	2022	A new series of quinolotacrine hybrids including cyclopenta- and cyclohexa-quinolotacrine derivatives were designed, synthesized, and assessed as anti-cholinesterase (ChE) agents.	quinolotacrine	16-30	butyrylcholinesterase	Rattus norvegicus	151-165	
34491490-3	2022	Of these compounds, cyclohexa-quinolotacrine hybrids displayed a little better anti-AChE activity than cyclopenta-quinolotacrine hybrids.	cyclohexa	20-29	acetylcholinesterase	Rattus norvegicus	84-88	
34491490-3	2022	Of these compounds, cyclohexa-quinolotacrine hybrids displayed a little better anti-AChE activity than cyclopenta-quinolotacrine hybrids.	quinolotacrine	30-44	acetylcholinesterase	Rattus norvegicus	84-88	
34491490-3	2022	Of these compounds, cyclohexa-quinolotacrine hybrids displayed a little better anti-AChE activity than cyclopenta-quinolotacrine hybrids.	cyclopenta-quinolotacrine	103-128	acetylcholinesterase	Rattus norvegicus	84-88	
34491490-8	2022	As a result, these quinolotacrine hybrids can be very encouraging AChE inhibitors to treat Alzheimer"s disease.	quinolotacrine	19-33	acetylcholinesterase	Rattus norvegicus	66-70	
34491490-9	2022	A novel series of quinolotacrine hybrids were designed, synthesized, and evaluated against AChE and BChE enzymes as potential agents for the treatment of AD.	quinolotacrine	18-32	acetylcholinesterase	Rattus norvegicus	91-95	
34491490-9	2022	A novel series of quinolotacrine hybrids were designed, synthesized, and evaluated against AChE and BChE enzymes as potential agents for the treatment of AD.	quinolotacrine	18-32	butyrylcholinesterase	Rattus norvegicus	100-104